Metagenomi (MGX) Competitors $1.49 -0.24 (-13.87%) Closing price 04:00 PM EasternExtended Trading$1.48 0.00 (-0.34%) As of 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MGX vs. CMPX, AVIR, TERN, ACB, SLDB, ATXS, SLRN, CDTX, HUMA, and DRUGShould you be buying Metagenomi stock or one of its competitors? The main competitors of Metagenomi include Compass Therapeutics (CMPX), Atea Pharmaceuticals (AVIR), Terns Pharmaceuticals (TERN), Aurora Cannabis (ACB), Solid Biosciences (SLDB), Astria Therapeutics (ATXS), Acelyrin (SLRN), Cidara Therapeutics (CDTX), Humacyte (HUMA), and Bright Minds Biosciences (DRUG). These companies are all part of the "pharmaceutical products" industry. Metagenomi vs. Compass Therapeutics Atea Pharmaceuticals Terns Pharmaceuticals Aurora Cannabis Solid Biosciences Astria Therapeutics Acelyrin Cidara Therapeutics Humacyte Bright Minds Biosciences Compass Therapeutics (NASDAQ:CMPX) and Metagenomi (NASDAQ:MGX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, community ranking, analyst recommendations and institutional ownership. Does the MarketBeat Community favor CMPX or MGX? Compass Therapeutics received 26 more outperform votes than Metagenomi when rated by MarketBeat users. However, 95.45% of users gave Metagenomi an outperform vote while only 81.03% of users gave Compass Therapeutics an outperform vote. CompanyUnderperformOutperformCompass TherapeuticsOutperform Votes4781.03% Underperform Votes1118.97%MetagenomiOutperform Votes2195.45% Underperform Votes14.55% Does the media favor CMPX or MGX? In the previous week, Compass Therapeutics had 6 more articles in the media than Metagenomi. MarketBeat recorded 9 mentions for Compass Therapeutics and 3 mentions for Metagenomi. Metagenomi's average media sentiment score of 0.85 beat Compass Therapeutics' score of 0.52 indicating that Metagenomi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Metagenomi 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings and valuation, CMPX or MGX? Compass Therapeutics has higher earnings, but lower revenue than Metagenomi. Compass Therapeutics is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCompass Therapeutics$850K302.60-$42.49M-$0.37-5.03Metagenomi$52.30M1.24-$68.25M-$2.62-0.66 Do analysts recommend CMPX or MGX? Compass Therapeutics currently has a consensus target price of $13.38, indicating a potential upside of 619.09%. Metagenomi has a consensus target price of $13.00, indicating a potential upside of 651.45%. Given Metagenomi's higher possible upside, analysts clearly believe Metagenomi is more favorable than Compass Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Compass Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Metagenomi 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Do insiders & institutionals have more ownership in CMPX or MGX? 68.4% of Compass Therapeutics shares are owned by institutional investors. 28.5% of Compass Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more volatility & risk, CMPX or MGX? Compass Therapeutics has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. Comparatively, Metagenomi has a beta of -0.27, suggesting that its stock price is 127% less volatile than the S&P 500. Is CMPX or MGX more profitable? Compass Therapeutics has a net margin of 0.00% compared to Metagenomi's net margin of -134.27%. Compass Therapeutics' return on equity of -32.37% beat Metagenomi's return on equity.Company Net Margins Return on Equity Return on Assets Compass TherapeuticsN/A -32.37% -30.67% Metagenomi -134.27%-43.23%-18.86% SummaryCompass Therapeutics beats Metagenomi on 13 of the 19 factors compared between the two stocks. Get Metagenomi News Delivered to You Automatically Sign up to receive the latest news and ratings for MGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGX vs. The Competition Export to ExcelMetricMetagenomiBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$64.67M$3.00B$5.56B$7.82BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-0.6630.4222.5118.48Price / Sales1.24498.92395.68103.60Price / CashN/A168.6838.1834.62Price / BookN/A3.206.774.25Net Income-$68.25M-$72.35M$3.22B$248.23M7 Day Performance-1.14%1.46%1.45%0.89%1 Month Performance31.06%8.79%3.97%3.53%1 Year Performance-75.43%-22.36%16.14%5.08% Metagenomi Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGXMetagenomi1.489 of 5 stars$1.49-13.9%$13.00+772.5%-75.4%$55.70M$52.30M-0.57236News CoverageCMPXCompass Therapeutics3.3837 of 5 stars$1.78+1.7%$13.38+651.4%+29.2%$246.14M$850,000.00-4.8120Analyst ForecastShort Interest ↑Analyst RevisionAVIRAtea Pharmaceuticals3.1558 of 5 stars$2.86-3.7%$6.00+109.8%-20.3%$244.60MN/A-1.3870Positive NewsTERNTerns Pharmaceuticals4.2794 of 5 stars$2.71+12.9%$18.38+578.0%-34.7%$236.58MN/A-2.3040Positive NewsACBAurora Cannabis0.6347 of 5 stars$4.20-5.4%N/A-49.7%$236.10M$320.81M84.021,340News CoverageSLDBSolid Biosciences3.9782 of 5 stars$3.03+18.8%$15.67+417.1%-62.7%$234.80M$8.09M-1.00100News CoverageHigh Trading VolumeATXSAstria Therapeutics2.5415 of 5 stars$4.11+1.7%$26.60+547.2%-43.8%$231.94MN/A-1.9730Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageSLRNAcelyrin3.0014 of 5 stars$2.28+3.6%$9.60+321.1%-40.9%$230.07MN/A-0.93135Positive NewsCDTXCidara Therapeutics4.2494 of 5 stars$20.69+6.4%$39.14+89.2%+74.4%$226.62M$1.28M-0.8190Upcoming EarningsAnalyst ForecastNews CoverageHUMAHumacyte2.6683 of 5 stars$1.45-13.7%$13.71+845.8%-63.0%$224.92M$1.57M-1.08150News CoverageDRUGBright Minds Biosciences3.3161 of 5 stars$31.89-3.7%$84.33+164.5%+2,970.0%$224.63MN/A-187.58N/ANews Coverage Related Companies and Tools Related Companies Compass Therapeutics Competitors Atea Pharmaceuticals Competitors Terns Pharmaceuticals Competitors Aurora Cannabis Competitors Solid Biosciences Competitors Astria Therapeutics Competitors Acelyrin Competitors Cidara Therapeutics Competitors Humacyte Competitors Bright Minds Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metagenomi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metagenomi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MGX Stock Free MGX Stock Alerts